KELLY ENNIS DEBRA J sold $418K of MO

Altria Group (MO) reported Q2 adjusted EPS of $1.48, below the $1.50 expected, on net revenue of about $6.11B. Net earnings fell 3.4% to $2.3B. Marlboro volume dropped 7.4% and On! fell 4.2%, leading Altria to narrow FY adjusted EPS guidance to $5.61-$5.72. The article cites a $74 valuation target and 6.5% dividend yield.

The U.S. FDA authorized marketing of four new flavored nicotine pouch products from brand “on!” and raised the total recently approved to 30. The FDA also previously cleared ZYN for 20 products with a “Modified Risk Tobacco Product” claim. Philip Morris makes ZYN and Altria makes “on!”. Health groups cite youth use and addiction risks; FDA says MRTP status does not mean risk-free.

The FDA authorized marketing of four On Plus nicotine pouch products made by Helix Innovations, a subsidiary of Altria. The FDA said the review was under a September pilot program and that the pouches have lower levels of most harmful and potentially harmful constituents versus other oral and smokeless products. Altria reported first-half 2026 net revenues up 1.6% to $11.5 billion.

Altria (MO) reported Q2 2026 adjusted diluted EPS of $1.48, up 2.8%, and $2.80 for the first half, up 4.9%. Full-year guidance was narrowed to $5.61 to $5.72. Smokeable OCI was $3.0B, up 2.4%, with Marlboro pricing strength. Capital returns included $3.6B dividends and $335M buybacks in H1.

Thursday, July 30, 2026 at 9:00 a.m. ET CALL PARTICIPANTS Vice President of Investor Relations - Mac Livingston Chief Executive Officer - Salvatore Mancuso Chief Financial Officer - Heather Newman TAKEAWAYS Adjusted Diluted EPS -- $1.48 for the second quarter, representing a 2.8% increase, and $2.80 for the first half, up 4.9%. Full-Year Guidance -- Narrowed to a range of $5.61 to $5.72, representing a growth rate of 3.5% to 5.5% from the 2025 base of $5.42.

Altria Group (MO) shares fell about 9% after quarterly results showed weaker demand. Smokable Products net revenues rose 0.7%, but domestic cigarette shipment volume fell 3.2%, with Marlboro down 7.4%. Oral tobacco volume declined 5.3%. Quarterly operating income fell 2.9% to $3.14B. Altria raised 2026 adjusted EPS guidance to $5.61-$5.72.